These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10084057)

  • 21. [Plasminogen activators and thrombolytic therapy].
    Taran LD
    Biomed Khim; 2005; 51(3):248-62. PubMed ID: 16104388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ideal fibrinolytic: can drug design improve clinical results?
    Van de Werf FJ
    Eur Heart J; 1999 Oct; 20(20):1452-8. PubMed ID: 10493843
    [No Abstract]   [Full Text] [Related]  

  • 23. [Thrombolytic therapy].
    Matsuda T
    Nihon Rinsho; 1998 Oct; 56(10):2577-81. PubMed ID: 9796322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombolytic therapy for myocardial infarction.
    Brophy J
    N Engl J Med; 1998 Feb; 338(8):545-6; author reply 546-7. PubMed ID: 9471557
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
    Ross AM; Gao R; Coyne KS; Chen J; Yao K; Yang Y; Qin X; Qiao S; Yao M;
    Am Heart J; 2001 Aug; 142(2):244-7. PubMed ID: 11479462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombolytic therapy for myocardial infarction.
    Frei S
    N Engl J Med; 1998 Feb; 338(8):545; author reply 546-7. PubMed ID: 9471556
    [No Abstract]   [Full Text] [Related]  

  • 28. Low incidence of hemorrhagic infarction following coronary reperfusion with nasaruplase in a canine model of acute myocardial infarction. Comparison with recombinant t-PA.
    Kido H; Hayashi K; Uchida T; Watanabe M
    Jpn Heart J; 1995 Jan; 36(1):61-79. PubMed ID: 7760515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Plasminogen activators as thrombolytic agents in myocardial infarction].
    Chamone DA; Massumoto C; Fujimura AY; Pileggi F; Bellotti G
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(6):288-94. PubMed ID: 2518605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New directions in thrombolytic therapy.
    Toombs CF
    Curr Opin Pharmacol; 2001 Apr; 1(2):164-8. PubMed ID: 11714091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New thrombolytic drugs in acute myocardial infarction: theoretical and practical considerations.
    Verstraete M
    Circulation; 1987 Aug; 76(2 Pt 2):II31-8. PubMed ID: 3111745
    [No Abstract]   [Full Text] [Related]  

  • 34. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic agents for acute evolving myocardial infarction: comparative effects.
    Sherry S
    Ration Drug Ther; 1987 Jan; 21(1):1-9. PubMed ID: 3112866
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular biology of plasminogen activators: what are the clinical implications of drug design?
    Smalling RW
    Am J Cardiol; 1996 Dec; 78(12A):2-7. PubMed ID: 8990404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of acute myocardial infarction by thrombolytic therapy in a patient with primary antiphospholipid antibody syndrome.
    Ho YL; Chen MF; Wu CC; Chen WJ; Lee YT
    Cardiology; 1996; 87(4):354-7. PubMed ID: 8793173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
    Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.